Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis

Harding, 2000, Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome, J Antimicrob Chemother, 45, 835, 10.1093/jac/45.6.835 Greenberg, 1990, Treatment of bone, joint and vascular-access-associated Gram-positive bacterial infections with teicoplanin, Antimicrob Agents Chemother, 34, 2392, 10.1128/AAC.34.12.2392 Outman, 1990, Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses, Antimicrob Agents Chemother, 34, 2114, 10.1128/AAC.34.11.2114 Pea, 2003, Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose, J Antimicrob Chemother, 51, 971, 10.1093/jac/dkg147 Schmit, 1992, Efficacy of teicoplanin for enterococcal infections: 63 cases and review, Clin Infect Dis, 15, 302, 10.1093/clinids/15.2.302 LeFrock, 1992, Teicoplanin in the treatment of bone and joint infections, Eur J Surg, 567, 9 Wilcox, 2004, Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections, J Antimicrob Chemother, 53, 335, 10.1093/jac/dkh088 Hidayat, 2006, High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections, Arch Intern Med, 166, 2138, 10.1001/archinte.166.19.2138 Schentag, 2001, Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit, Crit Care Med, 29, N100, 10.1097/00003246-200104001-00009 Kumar, 2006, Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock, Crit Care Med, 34, 1589, 10.1097/01.CCM.0000217961.75225.E9 Craig, 2003, Basis pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid, Infect Dis Clin North Am, 17, 479, 10.1016/S0891-5520(03)00065-5 Gould, 2008, Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus, Int J Antimicrob Agents, 31, 1, 10.1016/S0924-8579(08)70002-5 Weinbren, 2002, Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy, J Antimicrob Chemother, 50, 306, 10.1093/jac/dkf110 Cheesebrough, 1990, The potential impact on clinical practice of differences in the in-vitro activity of vancomycin and teicoplanin, J Antimicrob Chemother, 25, 716, 10.1093/jac/25.4.716-a Cepeda, 2004, Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study, J Antimicrob Chemother, 53, 345, 10.1093/jac/dkh048